{"summary":"Based in the United States, strong experience in medical monitoring oncology and immune-oncology drug, vaccine, and RNA discovery cell and gene therapy oncology studies encompass a wide across all phases with multinational teams of clinical trials development in the US, China, Canada, Europe, Norway, Russia, APAC, South Korea, Taiwan, Japan, Israel, South America, etc\n\nExtensive Global leadership experience with Risk Management, Pharmacovigilance, Medical Affairs I\/O  Immuno-Oncology experience, and Vaccination in combination with IO with NSCLC, UPS sarcoma , ACC tumor,immunotherapy, Lymphoma, SCCHN( Squamous Cell Carcinoma of the head and neck), UC (Urothelial Carcinoma ), Sarcoma, Glioma, TGCT\/Tenosynovial Giant Cell Tumor, GI: liver, stomach, colon, esophagus, respiratory, Urothelial Bladder Cancer, Cervix cancer, Epithelial Ovarian Cancer (ADC), Sex cord-stromal tumor, Sarcoma, Hepatocellular Carcinoma, Pancreas cancer, Triple-negative breast cancer, Carcinoma of the uterus, Tenosynovial giant cell tumor, Pancreatic Cancer, SCLC, Esophagus cancer, Melanoma, etc. ) Cervical Cancer, Endocervical sarcoma, serous uterine carcinoma, CRPS phase 2b, Prostate Cancer, Advanced colorectal cancer, Acute Myeloid Leukemia AML, and Myelodysplastic Syndrome, Rare Disease.Medical monitoring a clinical trial with \u201csecond generation,\u201d microbiome therapies single-strain live biotherapeutic products (LBP) with IO drug.Anti -HER2 therapy.\n23 years of global clinical development ( and preclinical) clinical trial design implementation\/execution of protocols, use of adaptive design, biomarkers, and digital endpoints. 13 publications. Clinical trial experience (Phase I-Phase II and Phase III) and post-marketing implementation and pharmacovigilance. 16 years of practice in medicine (MD and PI- primary investor). \n\nAccomplishes milestones and targets by facilitating cross-functional internal and external relationships. Strong ability to communicate with all levels of the organization. Highly dedicated and motivated individual with exceptional work ethic. Bilingual, English and Turkish \nSpecialties: Pharmacovigilance. Therapeutic Area Lead- Oncology ( Roche: pertuzumab\/ Perjeta) Immuno  Oncology (Ipilimumab\/Bristol Myers Squibb: nivolumab, BeiGene: Tislizumab), Avelumab,  immunology, Hematology,  Endocrinology(Diabetes& obesity),  Infectious disease, Respiratory disease, Cardiology drugs, Vascular Therapy and Cardiac Devices:  Coronary Artery Stent: Mitral&Aortic valves), GI  devices, Neurology Stroke\/Stroke prevention, TIA.\n\nPharmaceutical\/Biotechnology experience in APAC","lastName":"Pamuklar MD,PhD,MS","objectUrn":"urn:li:member:73550803","geoRegion":"Raleigh-Durham-Chapel Hill Area","fullName":"Zehra Nurgul Pamuklar MD,PhD,MS","firstName":"Zehra Nurgul","currentPositions":[{"companyName":"Labcorp Drug Development","title":"Senior Medical Director","tenureAtCompany":{"numYears":4,"numMonths":8},"companyUrnResolutionResult":{"website":"http:\/\/www.labcorp.com","formattedRevenue":{"unit":"BILLION","amount":10.4,"currencyCode":"USD"},"industry":"Hospitals and Health Care","employeeCountRange":"10001+","headquarters":{"geographicArea":"North Carolina","country":"United States","city":"Burlington","postalCode":"27215","line1":"531 South Spring Street"},"revenue":{"amount":"1.04414E+10","currencyCode":"USD"},"flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/labcorp\/"},"startedOn":{"month":9,"year":2022},"companyUrn":"urn:li:fs_salesCompany:164664"}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)","profilePictureDisplayImage":{"artifacts":[{"width":99,"fileIdentifyingUrlPathSegment":"100_100\/0\/1704467661617?e=1723075200&v=beta&t=tyinOckYlh2zyL9x2QwQW1VP8E6VWFVWxj5PZQOYfvY","height":100},{"width":199,"fileIdentifyingUrlPathSegment":"200_200\/0\/1704467661617?e=1723075200&v=beta&t=7unZLKkxGtoxZAg9GJlb3QQAij0HO-j0h6BquKX2vIQ","height":199},{"width":199,"fileIdentifyingUrlPathSegment":"400_400\/0\/1704467661617?e=1723075200&v=beta&t=lN-m0B8e77dbVDEIC1LjqSLwN3p1hhsP0rUyWf_jwg8","height":199},{"width":199,"fileIdentifyingUrlPathSegment":"800_800\/0\/1704467661617?e=1723075200&v=beta&t=gQfjUiEHtnCJrNmwtNzVWKmCeB4BzFiB5qvUsva2HNM","height":199}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E03AQEkJwTJiUvSJw\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Pharmaceutical Manufacturing","educations":[{"endedOn":{"month":8,"year":2011},"degree":"Master of Science (MS)","eduId":49855692,"schoolUrn":"urn:li:fs_salesSchool:3356","school":"urn:li:fs_salesSchool:3356","fieldsOfStudy":["Clinical Research Management"],"schoolName":"Duke University","startedOn":{"year":2009}},{"endedOn":{"year":1997},"degree":"Doctor of Philosophy (Ph.D.)","eduId":76877255,"schoolUrn":"urn:li:fs_salesSchool:32030","school":"urn:li:fs_salesSchool:32030","fieldsOfStudy":["Physiology\/Immunophysiology\/immunobiology"],"schoolName":"Gazi University College of Medicine","startedOn":{"year":1990}},{"endedOn":{"year":1985},"degree":"Doctor of Medicine - MD","eduId":423939158,"fieldsOfStudy":["Medicine-Became a licenced physician at 22"],"schoolName":"Ankara University Medical school","startedOn":{"year":1978}}],"skills":[{"numOfEndorsement":1,"name":"Clinical Monitoring"},{"numOfEndorsement":2,"name":"Biopharmaceuticals"},{"numOfEndorsement":26,"name":"Clinical Trials"},{"numOfEndorsement":14,"name":"Pharmacovigilance"},{"numOfEndorsement":13,"name":"Clinical Development"},{"numOfEndorsement":4,"name":"CTMS"},{"numOfEndorsement":5,"name":"Drug Development"},{"numOfEndorsement":2,"name":"SOP"},{"numOfEndorsement":2,"name":"FDA"},{"numOfEndorsement":2,"name":"Drug Discovery"},{"numOfEndorsement":1,"name":"3.\tDrug therapy positioning"},{"numOfEndorsement":2,"name":"7.\tMedicine"},{"numOfEndorsement":1,"name":"15.\tCardiology"},{"numOfEndorsement":1,"name":"16.\tOncology"},{"numOfEndorsement":1,"name":"19.\tCardiovascular Device(Aortic Valve, Coronary Stent)"},{"numOfEndorsement":1,"name":"Trial Management"},{"numOfEndorsement":1,"name":"CRO"},{"numOfEndorsement":1,"name":"1.\tPharmacovigilance  2.\tDrug Safety"},{"numOfEndorsement":0,"name":"6.\tDrug Development"},{"numOfEndorsement":0,"name":"8.\tCardiovascular science"},{"numOfEndorsement":0,"name":"10.\tCRO\/AOR"},{"numOfEndorsement":0,"name":"13.\tGastroenterology"},{"numOfEndorsement":0,"name":"14.\tEndocrinology"},{"numOfEndorsement":0,"name":"17.\tHematology"},{"numOfEndorsement":0,"name":"18.\tInfectious Diseases"},{"numOfEndorsement":0,"name":"20.\tICH-GCP"},{"numOfEndorsement":0,"name":"21.\tCTMS"},{"numOfEndorsement":0,"name":"22.\tGCP"},{"numOfEndorsement":0,"name":"23.\tRegulatory Affairs"},{"numOfEndorsement":0,"name":"24.\tClinical Research Management"},{"numOfEndorsement":0,"name":"25.\tPharmaceutical Industry"},{"numOfEndorsement":0,"name":"26.\tMedical Writing"},{"numOfEndorsement":0,"name":"27.\tMedical Affairs"},{"numOfEndorsement":0,"name":"28.\tClinical Study Design"},{"numOfEndorsement":0,"name":"29.\tFDA"},{"numOfEndorsement":0,"name":"31.\tSOW"},{"numOfEndorsement":1,"name":"32.\tClinical Monitoring"},{"numOfEndorsement":0,"name":"33.\tEDC"},{"numOfEndorsement":0,"name":"Clinical Pharmacology"},{"numOfEndorsement":0,"name":"35.\tAdobe Photoshop, MS Office (Word, PowerPoint, Excel etc.)"},{"numOfEndorsement":0,"name":"Protocol Development"},{"numOfEndorsement":0,"name":"Neurology"},{"numOfEndorsement":0,"name":"Project Management"},{"numOfEndorsement":0,"name":"Microsoft Office"},{"numOfEndorsement":0,"name":"Periodic Reports submission;PADER,PSUR,DSUR etc."},{"numOfEndorsement":0,"name":"Aggregate Reports review"},{"numOfEndorsement":0,"name":"Immunology"},{"numOfEndorsement":0,"name":"Rheumatology"},{"numOfEndorsement":0,"name":"Neuroscience"},{"numOfEndorsement":1,"name":"Medical Communications"}],"pronoun":"She\/Her","numOfConnections":2833,"patents":[],"headline":"Senior Medical Director at Fortrea Drug Development","courses":[{"name":"NIH ","number":"http:\/\/pcp.nihtraining.com\/certificate.php?year=2011&student_table_id=2121"}],"certifications":[{"companyUrn":"urn:li:fs_salesCompany:165107","authority":"The National Institutes of Health","name":"NIH Principles of Clinical Pharmacology","company":"urn:li:fs_salesCompany:165107","licenseNumber":"http:\/\/pcp.nihtraining.com\/certificate.php?year=2011&student_table_id=2121","startedOn":{"month":4,"year":2012}}],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/zehra-nurgul-pamuklar-md-phd-ms-15777020","organizations":[{"name":"The American Society of Clinical Oncology","description":"Member of The American Society of Clinical Oncology","position":"Member","startedOn":{"month":5,"year":2018}}],"location":"Raleigh-Durham-Chapel Hill Area","publications":[{"name":"Phosphodiesterase type 4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury","publishedOn":{"month":8,"year":2014},"publisher":"Arterioscler Thromb Vasc Biol","url":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4117992\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]},{"name":"Postprandial metabolite profiles reveal differential nutrient handling after bariatric surgery compared with matched caloric restriction","publishedOn":{"month":4,"year":2014},"publisher":"Ann Surg.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3901799\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]},{"name":"Effects of Roux-en-Y gastric bypass or diabetes support and education on insulin sensitivity and insulin secretion in morbidly obese patients with type 2 diabetes","publishedOn":{"month":3,"year":2014},"publisher":"Ann Surg.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Effects+of+Roux-en-Y+gastric+bypass+or+diabetes+support+and+education+on+insulin+sensitivity+and+insulin+secretion+in+morbidly+obese+patients+with+type+2+diabetes","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]},{"name":"Serum leptin levels are inversely correlated with omental gene expression of adiponectin and markedly decreased after gastric bypass surgery","publishedOn":{"month":5,"year":2012},"publisher":"Surg Endosc","url":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=.+Serum+leptin+levels+are+inversely+correlated+with+omental+gene+expression+of+adiponectin+and+markedly+decreased+after+gastric+bypass+surgery","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]},{"name":"Necdin-E2F4 interaction provides insulin-sensitizing effect after weight loss induced by gastric bypass surgery.","publishedOn":{"month":11,"year":2011},"publisher":"Surg Obes Relat Dis","url":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Necdin-E2F4+interaction+provides+insulin-sensitizing+effect+after+weight+loss+induced+by+gastric+bypass+surgery.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]},{"name":"Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction","publishedOn":{"month":4,"year":2012},"publisher":"Surg Endosc","url":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Gastric+bypass+surgery+restores+meal+stimulation+of+the+anorexigenic+gut+hormones+glucagon-like+peptide-1+and+peptide+YY+independently+of+caloric+restriction","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]},{"name":"Autotaxin\/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis","publishedOn":{"month":1,"day":12,"year":2009},"url":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Autotaxin%2Flysopholipase+D+and+lysophosphatidic+acid+regulate+murine+hemostasis+and+thrombosis","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]},{"name":"AJ  Therapeutic potential of autotaxin\/lysophospholipase d inhibitors","publishedOn":{"month":8,"year":2008},"publisher":"Curr Drug Targets","url":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/?term=Therapeutic+potential+of+autotaxin%2Flysophospholipase+d+inhibitors.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]},{"name":"Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway.","publishedOn":{"month":3,"year":2008},"publisher":"Arterioscler Thromb Vasc Biol.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18202325","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]},{"name":"Effects of unfractionated heparin and glycoprotein IIb\/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils.","publishedOn":{"month":8,"year":2007},"publisher":"Arterioscler Thromb Vasc Biol","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17525363","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]},{"name":"Src family kinases mediate neutrophil adhesion to adherent platelets","publishedOn":{"month":3,"year":2007},"publisher":"Blood.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17095622","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]},{"name":"Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets: studies using chemical inhibitors of lipid phosphate phosphatase activity","publishedOn":{"month":8,"day":3,"year":2003},"publisher":"J Biol Chem.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=.+Lipid+phosphate+phosphatases+regulate+lysophosphatidic+acid+production+and+signaling+in+platelets%3A+studies+using+chemical+inhibitors+of+lipid+phosphate+phosphatase+activity","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]},{"name":"Safety and PK\/PD Results of First human Phase 1 Study of Pimicotinib ABSK021), a CSF-1R inhibitor , in Patients with Advanced Solid Tumors","publishedOn":{"month":2,"day":10,"year":2023},"publisher":"ASCO abstract ","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARiS9MBi00GekfgtkmUFMrA6dG1XoYUJmQ,NAME_SEARCH,S8kM)"}]}],"positions":null,"posts":[{"createdAt":1715106060000,"insightId":"aaea239e-71a8-440c-b7ac-a957dc3773fa","activityUnion":{"postActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQFUSD1Fd6jdRg\/image-shrink_1280\/0\/1715106104443?e=1717977600&v=beta&t=nkioNvHwqUoFBAZOpzezr9d5imq6Q1a3uH4c4t6E8x8","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQFUSD1Fd6jdRg\/image-shrink_1280\/0\/1715106104443?e=1717977600&v=beta&t=nkioNvHwqUoFBAZOpzezr9d5imq6Q1a3uH4c4t6E8x8"}]},"description":"Join this webinar to cover key questions about innovative approaches to keeping clinical development on track to meet timelines and other key performance indicators....","resolvedUrl":"http:\/\/pbynd.co\/pcj4e","title":"Accelerating Clinical Development through Design, Diversity & Digitalization in Oncology and Beyond"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":7},{"type":"PRAISE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7193676408202702848","threadUrn":"urn:li:activity:7193676408202702848","reactionsCount":9,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7193676407711879168","message":{"attributes":[],"text":"Join this webinar to cover key questions about innovative approaches to keeping clinical development on track to meet timelines and other key performance indicators.\nThursday, May 16, 2024 | 10am EDT (NA) \/ 3PM BST (UK) \/ 4PM CEST (EU-Central) "},"entityUrn":"urn:li:share:7193676407711879168"}}},{"createdAt":1717159740000,"insightId":"0e761ae4-f216-41e5-b493-53df38dc3352","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7202241106078580737,7202290178558701568)","threadUrn":"urn:li:ugcPost:7202241106078580737","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Alisan"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7202241106078580737"}}},{"createdAt":1715606820000,"insightId":"74a2d0fd-ca7c-4bc9-9ffa-5108d61a5d49","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7195415073408929792,7195776602373242882)","threadUrn":"urn:li:ugcPost:7195415073408929792","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Kamal!!!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7195415073408929792"}}},{"createdAt":1713967860000,"insightId":"9b45bacd-a5fc-405e-8cd2-644e9571b065","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7188869719460913152,7188902500366733312)","threadUrn":"urn:li:activity:7188869719460913152","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations Cheerag!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7188869719460913152"}}},{"createdAt":1712772660000,"insightId":"6c93cecb-d228-4489-a242-cff1a5c87697","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7183371496537350145,7183889398793412609)","threadUrn":"urn:li:activity:7183371496537350145","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations Laura!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7183371496537350145"}}}]}